OMEROS CORP.
-
USD
(-)
- 15 min delayed data - NASDAQ Stocks
| Open: | - |
| Change: | - |
| Volume: | - |
| Low: | - |
| High: | - |
| High / Low range: | - |
| Type: | Stocks |
| Ticker: | OMER |
| ISIN: |
OMEROS CORP. news, videos and press releases - Page 2
For more news please use our advanced search feature.
OMEROS CORP. - More news...
OMEROS CORP. - More news...
- 11/08/2022 - 13:30 Omeros Corporation Receives Decision from FDA on Formal Dispute Resolution Request for Narsoplimab
- 11/04/2022 - 13:00 Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2022
- 11/03/2022 - 13:00 Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
- 10/03/2022 - 11:10 Omeros Corporation Announces Royalty Monetization Transaction with DRI Healthcare Trust
- 09/15/2022 - 13:06 Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial
- 09/15/2022 - 13:02 I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Reports Assessment of Narsoplimab for Treatment of Critically Ill Patients With COVID-19
- 08/17/2022 - 12:40 Omeros Corporation Receives Interim Response from FDA on Formal Dispute Resolution Request for Narsoplimab
- 08/09/2022 - 20:02 Omeros Corporation Reports Second Quarter 2022 Financial Results
- 08/04/2022 - 12:30 Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2022
- 07/29/2022 - 12:45 FDA Grants Orphan Drug Designation to Omeros’ MASP-3 Inhibitor OMS906 for Treatment of Paroxysmal Nocturnal Hemoglobinuria
- 06/15/2022 - 12:00 Omeros Announces Webcast Details for Annual Meeting of Shareholders
- 05/10/2022 - 20:02 Omeros Corporation Reports First Quarter 2022 Financial Results
- 05/04/2022 - 12:30 Omeros Corporation to Announce First Quarter Financial Results on May 10, 2022
- 04/20/2022 - 12:45 Omeros Announces Journal of Clinical Oncology Publication Detailing Pivotal Trial Results for Narsoplimab in HSCT-TMA
- 03/01/2022 - 21:02 Omeros Corporation Reports Fourth Quarter and Year-End 2021 Financial Results
- 02/24/2022 - 12:00 Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 1, 2022
- 01/19/2022 - 22:52 Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA
- 12/23/2021 - 14:10 Omeros Completes Sale of OMIDRIA® Franchise to Rayner Surgical
- 12/20/2021 - 14:30 OMER EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Omeros Corporation Investors with Losses to Inquire About Class Action Investigation - OMER
- 12/02/2021 - 12:30 Omeros Announces Agreement to Sell OMIDRIA® Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion
- 11/09/2021 - 21:02 Omeros Corporation Reports Third Quarter 2021 Financial Results
- 11/05/2021 - 12:40 Omeros Announces Results From Nearly Three-Year Follow-up of Patients in Phase 2 IgA Nephropathy Trial
- 11/05/2021 - 12:30 Omeros’ Narsoplimab Stabilized Kidney Function and Reduced Urinary Complement Proteins in a Patient with IgA Vasculitis
- 11/04/2021 - 12:30 Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2021
- 10/18/2021 - 10:30 Omeros Receives Complete Response Letter from FDA for Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA
- 10/16/2021 - 01:45 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
- 10/08/2021 - 02:30 OMEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating Omeros Corporation on Behalf of Omeros Stockholders and Encourages Investors to Contact the Firm
- 10/08/2021 - 01:45 OMER EQUITY ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Omeros Corporation Investors with Losses to Inquire About Class Action Investigation - OMER
- 10/07/2021 - 16:16 INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation and Encourages Investors with Losses to Contact the Firm
- 10/06/2021 - 20:00 Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Omeros Corporation (OMER) on Behalf of Investors
